RECURSION PHARMACEUTICALS, INC. (RXRX): Results of Operations and Financial Condition

RECURSION PHARMACEUTICALS, INC. (RXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently p

Event · Earnings
Role
supplier

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 15, 2026, 12:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RXRX
Bullish
high confidence
Mentioned
$RXRX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RXRXBullishMed
01

Why it matters

The cash inflow improves near‑term earnings visibility and validates the AI platform's commercial relevance, likely prompting short‑term buying.

02

Market read

First‑report milestone payment provides fresh revenue and underscores the strategic value of AI in pharma, offering a short‑term catalyst for RXRX.

03

What to watch

Potential dilution from future financing needs and execution risk of the candidate's Phase 1 trial could temper the positive reaction.

Relevance 7/10Novelty 7/10Timing: pre‑market today
AlphAI · Earnings readRXRX · third quarter of 2026

Sanofi optioned the first development candidate from its collaboration with Recursion, triggering a $10 million milestone payment to be recognized as revenue in the third quarter of 2026.

✓Solid quarter

The filing reports a meaningful collaboration milestone, revenue recognition of a $10 million payment in the third quarter of 2026, and transfer of further development and commercialization responsibility to Sanofi. It does not provide a complete quarterly financial-results release.

Revenue
$10M

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Sanofi option milestone paymentother$10M––
Milestone payment to be recognized as revenue in the third quarter of 2026other$10M––
Total upfront and milestone payments received from Sanofi under the collaborationother$144M––
Additional potential milestones for the optioned programothermore than $300 million––
Progress-based milestones achieved across the Recursion-Sanofi collaborationothersix progress-based milestones across five programs––

2027 and over the next 12 months outlook

  • NoteThe candidate is expected to enter phase 1 clinical trials in 2027.
  • NoteOver the next 12 months, other programs in the joint portfolio have the potential to reach development candidate and other progress-based milestones.

What drove it

  • Sanofi optioned the first development candidate from the companies’ multi-program research collaboration.
  • The potential first-in-class oral small molecule was designed against a challenging dual target implicated in inflammatory disease.
  • The candidate was delivered through Recursion’s integrated AI-enabled drug design platform and small-molecule chemistry capabilities combined with Sanofi’s drug-discovery and immunology expertise.
  • Sanofi will fund and lead further development and commercialization of the optioned candidate.
  • The option ends Recursion’s operational requirements related to this candidate, with all future payments resulting in profit to Recursion.

Concerns

  • The candidate is expected to enter phase 1 clinical trials in 2027 and remains subject to clinical-development, safety, efficacy, regulatory, and commercialization risks.
  • Sanofi retains discretion over option exercises, program advancement, and funding and may delay, deprioritize, or discontinue development of the optioned candidate.
  • More than $300 million in additional milestones and royalties are contingent on future program progress and successful commercialization.
  • The filing contains no complete income statement, cash flow statement, balance sheet, or quarterly operating-expense disclosure.

What to watch

  • Recognition of the $10 million milestone payment as revenue in the third quarter of 2026.
  • Initiation of the optioned candidate’s planned phase 1 clinical study in 2027.
  • Potential development-candidate and other progress-based milestones from additional programs in the joint portfolio over the next 12 months.
  • Sanofi’s continued funding and advancement of the optioned program.

Balance sheet and cash flow

  • The $10 million milestone payment will be recognized as revenue in the third quarter of 2026.
  • Sanofi’s selection of the development candidate triggered a $10 million milestone payment to Recursion.

Analysis

This Item 2.02 filing is a collaboration-development update rather than a complete quarterly earnings release. Sanofi optioned the first development candidate from the companies’ multi-program research collaboration, triggering a $10 million milestone payment. Recursion states that this payment will be recognized as revenue in the third quarter of 2026, but the filing does not report total third-quarter revenue or any other complete quarterly financial results.

The option raises total upfront and milestone payments received from Sanofi under the collaboration to $144 million. The companies have achieved six progress-based milestones across five programs. Recursion remains eligible for more than $300 million in additional milestones for the optioned program, along with an average of low double-digit royalties on net product sales if it is successfully commercialized.

The operational structure changes favorably for Recursion on the optioned program: Sanofi will fund and lead further development and commercialization, while the option ends Recursion’s operational requirements related to this candidate. Recursion states that all future payments related to the candidate will result in profit to Recursion. The candidate has been added to Sanofi’s development pipeline and is expected to enter phase 1 clinical trials in 2027.

The milestone supports the stated utility of Recursion’s platform in progressing a complex dual-target small-molecule design program. The company attributes delivery of the candidate to iterative computational prediction, chemical design, synthesis, and experimental validation, combined with Sanofi’s drug-discovery and immunology expertise. The filing also identifies further potential milestone activity, stating that other joint-portfolio programs could reach development-candidate and other progress-based milestones over the next 12 months.

The principal limitation is that the filing provides no total revenue, expenses, profitability, cash balance, cash flow, or balance-sheet data for the third quarter of 2026. The future economic value remains contingent on development progress, clinical outcomes, regulatory approval, commercialization, and Sanofi’s decisions on funding and program prioritization.

Management, verbatim

The most important test of any technology platform in drug discovery is whether it can translate into differentiated medicines. Together with Sanofi, we tackled a difficult design problem against a dual target product profile with high potential and delivered a molecule that Sanofi has now selected for its development pipeline. With additional programs advancing across our collaboration, this milestone is another important demonstration of how our platform can translate computational capabilities into differentiated medicines — and do so repeatedly.

Najat Khan, Ph.D., President and Chief Executive Officer of Recursion

By combining Sanofi's drug discovery and clinical and translational knowledge in Immunology with Recursion's AI-driven platform, we were able to move with speed and precision in a space where that balance is notoriously hard to achieve. This new development candidate has potential to deliver a differentiated oral medicine with highly selective dual targeting that could be a meaningful advance for people living with inflammatory diseases who still lack adequate treatment options.

Alyssa Johnsen, Therapeutic Area Head, Development, Immunology & Inflammation, Sanofi

Not in the filing

stated, not guessed
  • Period-end date for the third quarter of 2026
  • Total revenue for the third quarter of 2026
  • Revenue comparison with the prior-year period
  • Revenue comparison with the prior quarter
  • Gross profit and gross margin
  • Operating expenses
  • Operating income or loss
  • Net income or loss
  • GAAP earnings or loss per share
  • Non-GAAP earnings or loss per share
  • Operating cash flow
  • Free cash flow
  • Cash and cash equivalents
  • Debt
  • Share repurchases
  • Dividends
  • Revenue, margin, operating-expense, or tax-rate financial guidance
  • The previous outlook covered the full year 2026 with no quarterly guidance, and this release reports only the third quarter, so there is nothing to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Recursion announced a new Sanofi‑optioned immunology candidate, triggering a $10 million milestone and unlocking further upside under the existing collaboration.

Company-level read

Ticker impact

$RXRXBullishHigh confidence
Context

Recursion Pharma received a $10 million milestone payment from Sanofi, recognized as Q3 2026 revenue, and is eligible for up to $300 million in future milestones.

Expected impact

upward pressure as the market prices in the new cash inflow and future upside potential.

Evidence & confidence

First‑report 8‑K disclosure of a material cash milestone; investors typically react positively to confirmed revenue and large upside milestones.

Market effects

Highlights the value of AI‑driven drug discovery partnerships, potentially boosting sentiment for other biotech firms using similar platforms.

US biotech sector may see modest uplift; European partner Sanofi gains a pipeline addition but impact is limited.

Reinforces investor interest in AI‑enabled pharma collaborations worldwide.

Counterpoint

The $10 million milestone is modest relative to Recursion's cash burn; future milestones are uncertain and may not materialize, limiting upside.

Key entities

  • Recursion Pharmaceuticals, Inc.

    Clinical‑stage AI‑driven drug discovery firm (NASDAQ: RXRX).

  • Sanofi

    Global pharmaceutical partner receiving the optioned candidate.

Every RXRX earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.